Market Watch (Free subscription) | 08/19/2008
Amylin Pharmaceuticals leads drug stocks lower as shares of the biotech group lost ground for the second day over safety concerns about its diabetes drug Byetta.
Diabetes Notes (Free subscription) | yesterday
A new class of diabetes drugs, tipped to rake in billions of dollars, faces an uncertain future following six cases of severe pancreas inflammation linked to Amylin and Eli Lilly’s Byetta. So-called GLP-1 drugs like Byetta — and similar products being developed by firms including Novo Nordisk and Roche — are seen as a [...]
Market Watch (Free subscription) | 08/19/2008
LONDON (MarketWatch) -- Shares of Novo Nordisk traded 3% lower in Copenhagen on concerns that the Danish's firm's own diabetes drug may exhibit similar problems to Eli Lilly and Amylin's Byetta. "Obviously if liraglutide has the same side-effects as Byetta, it will have a negative impact on the approval process. We believe that Novo Nordisk several times has repeated, that no incidences of pancreatitis...
Business Wire (Free subscription) | 08/18/2008
One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.
Red Orbit (Free subscription) | 08/12/2008
WALTHAM, Mass., Aug.
Patent Baristas (Free subscription) | 08/08/2008
In a nonprecedential opinion, the U.S. Court of Appeals for the Federal Circuit gave the thumbs up to a district court decision that Plaintiff-Appellant Novo Nordisk A/S wasn’t getting a preliminary injunction out of Sanofi-Aventis after alleging that Sanofi’s SoloStar product infringed claims of Novo’s U.S. Patent No. 7,241,278. Novo Nordisk A/S v. Sanofi-Aventis (08-1225). In [...]
The News Market (Free subscription) | 08/07/2008
Danish pharmaceutical company Novo Nordisk reported a 13% increase in sales in the first-half of 2008 to DKK 21,724 ($ 4506) million compared with DKK 20,381 ($ 4227) million during the same
Market Watch (Free subscription) | 08/07/2008
LONDON (MarketWatch) -- Danish pharmaceutical firm Novo Nordisk said Thursday that first-half net profit fell 13% to 4.65 billion Danish kroner ($964 million). Last year's profit was boosted by an asset sale gain of 1.4 billion kroner. Sales increased 7% to 21.7 billion kroner. For 2008, the company raised its reported operating profit growth guidance to between 22% and 25%. "We are very pleased with...
Market Wire (Free subscription) | 08/07/2008
BAGSVAERD, DENMARK (MARKET WIRE) Financial statement for the period 1 January 2008 to 30 June 2008
Fiercebiotech (Free subscription) | 08/07/2008
Novo Nordisk's push to explore new therapeutic areas has brought it to Seattle, WA, where the Danish company plans to open a research center. The developer, which is known for its diabetes drugs, is pursuing development of oncology and inflammation drugs, and Seattle seems like just the place to do that. "There is a pool of talent in Seattle and a track record of therapeutic discovery here," Don Foster,...
John Cook's Venture Blog (Free subscription) | 08/06/2008
There's been plenty of bad news in the Seattle life science industry lately, with companies such as MDRNA, Amgen and Northstar Neuroscience cutting staff. So, Joe Tartakoff's report that Novo Nordisk plans to hire as many as 80 employees for a new research and development center here should be welcome news.
Market Wire (Free subscription) | 08/04/2008
BAGSVAERD, DENMARK (MARKET WIRE) Novo Nordisk A/S - Share repurchase programme
Jim Cramer's Mad Money (Free subscription) | 08/01/2008
Jim Cramer’s Mad Money Stock Picks for Thursday July 31 2008. These are all of Jim Cramer’s stock picks that are a Buy! I bold my picks. Buy: Allergan (AGN) Frontline (FRO) Petrohawk Energy (HK) Coca-Cola (KO) Nordic American Tanker (NAT) National Oilwell Varco (NOV) Novo Nordisk A/S (NVO) Pepsico (PEP) Research In Motion (RIMM) Sell: ACE Limited (ACE) Alon USA (ALJ) China Telecom (CHA) Grey Wolf (GW)...
IPBiz (Free subscription) | 08/01/2008
The CAFC noted: In this case, the district court denied the preliminary injunction because the patentee failed to show a reasonable likelihood of success on the merits. (...) After reviewing the intrinsic record, we cannot conclude that the district court abused its discretion. The district court found that a question exists regarding whether “the very character of the invention requires direct gearing...
Pharmalot (Free subscription) | 07/29/2008
The Danish drug maker says the employee, who was not identified, had no managerial position but “had access to information, which may influence Novo Nordisk’s share price,” the world’s largest producer of insulin says in a statement. The employee was charged Monday with unlawful insider trading in the company’s shares, and Novo Nordisk says it is [...]
